倍他索洛尔治疗轻中度原发性高血压的疗效评价  

Therapeutic Efficacy of Betaxolol in Mild and Moderate Essential Hypertension

作　　者：明广华[1,2] 陈红[1,2] 张宇清[1,2] 王静 胡恒慧[1,2] 黄建凤 党爱民 徐成斌[1,2] 刘国仗[1,2] 陶萍 

机构地区：[1]中国医学科学院中国协和医科大学心血管病研究所阜外心血管病医院高血压研究室 [2]北京医科大学人民医院

出　　处：《中国循环杂志》1997年第5期364-366,共3页Chinese Circulation Journal

摘　　要：目的：观察倍他索洛尔降压疗效、谷峰比值及不良反应。方法：采用随机双盲法、与另一β１受体阻滞剂比索洛尔作平行对照。１２８名３０～６５岁不拘性别的轻、中度原发性高血压患者，服安慰剂２周后，舒张压１２．６～１５．３ｋＰａ（９５～１１５ｍｍＨｇ）、收缩压≤２４．６ｋＰａ（１８５ｍｍＨｇ）者，进入研究。治疗组（ｎ＝６２）每日服倍他索洛尔１０～２０ｍｇ；对照组（ｎ＝６６）每日服比索洛尔５～１０ｍｇ，共４周。服用倍他索洛尔的２２例完成了２４小时动态血压监测。结果：治疗组收缩压及舒张压分别下降２．４及２．０ｋＰａ（１８及１５ｍｍＨｇ）；对照组相应值为２．７及２．０ｋＰａ（２０及１５ｍｍＨｇ）。动态血压监测结果显示：服倍他索洛尔４周后总血压负荷，昼夜平均收缩压与舒张压明显下降，收缩压及舒张压谷峰比值均大于５０％。两组不良反应少，各项生化指标无明显变化。结论：倍他索洛尔系第２代长效β１受体阻滞剂，可以做为治疗轻中度原发性高血压的药物。Objective:To investigate the hypotensive effect of betaxolol(Beta)in patients with essential hypertension. Methods:After taking 2 week placebo,128 patients with systolic blood pressure(SBP)≤24.6 kPa(185 mmHg) and diastolic blood pressure(DBP)between 12.6—15.3 kPa(95—115 mmHg)were selected.A double blind parallel study was carried out and randomly divided into Beta(10—20 mg/d, n =62) and bisoprolol(Biso)(5—10 mg/d, n =66)groups.Ambulatory blood pressure(ABP)was also monitored in 22 cases of Beta group. Results:In Beta group,the SBP and DBP decreased by 2.4 and 2.0 kPa (18 and 15 mmHg),while in Biso Group the SBP and DBP decreased by 2.7and 2.0 kPa (20 and 15 mmHg),respectively.No significant difference was found between two groups.The ABP showed that the total pressure load,the mean SBP and DBP at day and night were lowered apparently,the trough to peak ratios of both SBP and DBP were greater than 50%. Conclusion:Betaxolol,a long acting β 1 blocker,is an effective and safe hypotensive agent,and suitable to patients with mild and moderate essential hypertension.

关 键 词：高血压 原发性 药物疗法 倍他索洛尔 

分 类 号：R544.105[医药卫生—心血管疾病]